LT3600B - Nucleic acid fragment which codes for human proapolipoprotein a-i - Google Patents

Nucleic acid fragment which codes for human proapolipoprotein a-i Download PDF

Info

Publication number
LT3600B
LT3600B LTIP828A LTIP828A LT3600B LT 3600 B LT3600 B LT 3600B LT IP828 A LTIP828 A LT IP828A LT IP828 A LTIP828 A LT IP828A LT 3600 B LT3600 B LT 3600B
Authority
LT
Lithuania
Prior art keywords
sequence
human
dna sequence
proapo
dna
Prior art date
Application number
LTIP828A
Other languages
English (en)
Lithuanian (lt)
Inventor
Alex Bollen
Jean Gobert
Ernst Wuelfert
Original Assignee
Ucb Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ucb Sa filed Critical Ucb Sa
Publication of LTIP828A publication Critical patent/LTIP828A/xx
Publication of LT3600B publication Critical patent/LT3600B/lt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/775—Apolipopeptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • C12P21/02—Preparation of peptides or proteins having a known sequence of two or more amino acids, e.g. glutathione
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Medicinal Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Steroid Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Saccharide Compounds (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
LTIP828A 1987-05-28 1993-08-03 Nucleic acid fragment which codes for human proapolipoprotein a-i LT3600B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB878712540A GB8712540D0 (en) 1987-05-28 1987-05-28 Expression of human proapolipoprotein a-i

Publications (2)

Publication Number Publication Date
LTIP828A LTIP828A (en) 1995-02-27
LT3600B true LT3600B (en) 1995-12-27

Family

ID=10618034

Family Applications (1)

Application Number Title Priority Date Filing Date
LTIP828A LT3600B (en) 1987-05-28 1993-08-03 Nucleic acid fragment which codes for human proapolipoprotein a-i

Country Status (33)

Country Link
US (1) US5059528A (xx)
EP (1) EP0293357B1 (xx)
JP (1) JP2634193B2 (xx)
KR (1) KR970000808B1 (xx)
CN (1) CN1031892C (xx)
AT (1) ATE89006T1 (xx)
AU (1) AU615654B2 (xx)
CA (1) CA1323851C (xx)
CY (1) CY1809A (xx)
CZ (1) CZ283648B6 (xx)
DD (1) DD291093A5 (xx)
DE (1) DE3880739T2 (xx)
DK (1) DK175686B1 (xx)
EG (1) EG19101A (xx)
ES (1) ES2054878T3 (xx)
FI (1) FI100056B (xx)
GB (1) GB8712540D0 (xx)
HK (1) HK137794A (xx)
HU (1) HU204562B (xx)
IE (1) IE62422B1 (xx)
IL (1) IL86480A (xx)
LT (1) LT3600B (xx)
LV (1) LV5288A3 (xx)
NO (1) NO179253C (xx)
NZ (1) NZ224808A (xx)
PL (1) PL158064B1 (xx)
PT (1) PT87562B (xx)
RU (1) RU2009198C1 (xx)
SG (1) SG131594G (xx)
SK (1) SK279166B6 (xx)
SU (1) SU1834904A3 (xx)
UA (1) UA19765A (xx)
ZA (1) ZA883824B (xx)

Families Citing this family (61)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU587989B2 (en) * 1984-10-16 1989-09-07 Mitsubishi Chemical Corporation DMA fragments, expression vectors, proteins, hosts, and process for production of the proteins
JP2606228B2 (ja) * 1987-09-18 1997-04-30 三菱化学株式会社 ヒトプロアポリポプロテインａ−ｉ様蛋白の産生法
DE68917379T2 (de) * 1988-05-31 1994-12-01 Mitsubishi Chem Ind Verfahren zur Herstellung von Proteinen, die ähnlich dem natürlich-menschlichen Apolipoprotein-E sind.
US5846799A (en) * 1988-06-14 1998-12-08 La Region Wallone Human myeloperoxidase and its therapeutic application
US5460961A (en) * 1988-06-14 1995-10-24 La Region Wallonne Human myeloperoxidase and its therapeutic application
IT1229996B (it) * 1989-04-20 1991-09-20 Cesare Sirtori Espressione di apolipoproteina ai e apolipoproteina ai-milano in lievito e composizioni farmaceutiche che contengono dette apolipoproteine.
WO1992009698A1 (en) * 1990-11-26 1992-06-11 Genetics Institute, Inc. Expression of pace in host cells and methods of use thereof
US5844097A (en) * 1990-11-30 1998-12-01 Monoclonetics International, Inc. Methods for the diagnosis of peripheral nerve damage
ATE132269T1 (de) * 1990-11-30 1996-01-15 Monoclonetics Int Verfahren zur diagnose chronischer niedriger rückenschmerzen und nackenschmerzen
SE9500778D0 (sv) 1995-03-03 1995-03-03 Pharmacia Ab Process for producing a protein
US5994061A (en) * 1995-09-29 1999-11-30 Queen's University At Kingston DNA constructs and methods for screening for increased expression of human apo AI gene
SE9603068D0 (sv) * 1996-08-23 1996-08-23 Pharmacia & Upjohn Ab Process for purifying a protein
SE9603303D0 (sv) 1996-09-11 1996-09-11 Pharmacia & Upjohn Ab Process for purifying a protein
SE9603304D0 (sv) 1996-09-11 1996-09-11 Pharmacia & Upjohn Ab Process for purifying a compound
KR100330355B1 (ko) * 1999-06-04 2002-04-01 장인순 회전유동발생 날개를 가진 덕트형 핵연료 집합체 지지격자
US20040047853A1 (en) * 2000-06-09 2004-03-11 Dahl Soren W Purified proenzyme of dipeptidyl peptidase i (pro-dppi)
AU2002232642B2 (en) * 2000-12-12 2007-02-01 Lexicon Pharmaceuticals, Inc. Novel human kinases and uses thereof
KR100560102B1 (ko) * 2004-06-25 2006-03-13 한국생명공학연구원 프로아포리포단백질 ａ－ⅰ 변이체와, 이를 포함하는고지혈증 또는 동맥경화증 예방 및 치료제
US7427662B2 (en) * 2005-02-01 2008-09-23 Baord Of Supervisors Of Louisiana State University And Agricultural And Mechanical College Inhibition of angiogenesis and destruction of angiogenic vessels by apolipoprotein A-I and high density lipoprotein
US8206750B2 (en) 2005-03-24 2012-06-26 Cerenis Therapeutics Holding S.A. Charged lipoprotein complexes and their uses
CA2619943A1 (en) * 2005-08-26 2007-03-01 Cerenis Therapeutics Holding Sa Compositions and methods for producing apolipoprotein gene products in lactic acid bacteria
US20080293102A1 (en) * 2007-02-28 2008-11-27 Cerenis Therapeutics Holding, S.A. Compositions and methods for producing apolipoprotein
CN102239260B (zh) * 2008-10-03 2017-04-12 库尔纳公司 通过抑制针对载脂蛋白‑a1的天然反义转录物治疗载脂蛋白‑a1相关疾病
MX359674B (es) 2008-11-10 2018-10-05 Alnylam Pharmaceuticals Inc Lipidos y composiciones novedosas para el suministro de terapeuticos.
AU2010208035B2 (en) 2009-01-29 2016-06-23 Arbutus Biopharma Corporation Improved lipid formulation for the delivery of nucleic acids
CN104922699B (zh) 2009-03-12 2020-07-24 阿尔尼拉姆医药品有限公司 脂质配制的组合物以及用于抑制Eg5和VEGF基因表达的方法
JP5769701B2 (ja) 2009-05-05 2015-08-26 テクミラ ファーマシューティカルズ コーポレイションＴｅｋｍｉｒａ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｃｏｒｐｏｒａｔｉｏｎ 脂質組成物
CN103223177B (zh) 2009-05-06 2016-08-10 库尔纳公司 通过针对脂质转运和代谢基因的天然反义转录物的抑制治疗脂质转运和代谢基因相关疾病
KR102205886B1 (ko) 2009-06-10 2021-01-21 알닐람 파마슈티칼스 인코포레이티드 향상된 지질 조성물
AP3574A (en) 2009-08-14 2016-02-08 Alnylam Pharmaceuticals Inc Lipid formulated compositions and methods for inhibiting expression of a gene from the ebola virus
US10894098B2 (en) 2012-04-09 2021-01-19 Signablok, Inc. Methods and compositions for targeted imaging
US10525152B2 (en) 2009-10-09 2020-01-07 Signablok, Inc. Methods and compositions for targeted imaging
EP3296398A1 (en) 2009-12-07 2018-03-21 Arbutus Biopharma Corporation Compositions for nucleic acid delivery
US20130017223A1 (en) 2009-12-18 2013-01-17 The University Of British Columbia Methods and compositions for delivery of nucleic acids
WO2011139911A2 (en) 2010-04-29 2011-11-10 Isis Pharmaceuticals, Inc. Lipid formulated single stranded rna
WO2011143362A1 (en) 2010-05-11 2011-11-17 Esperion Therapeutics, Inc. Dimeric oxidation-resistant apolipoprotein a1 variants
EP2575764B1 (en) 2010-06-03 2017-04-19 Alnylam Pharmaceuticals, Inc. Biodegradable lipids for the delivery of active agents
US20130202652A1 (en) 2010-07-30 2013-08-08 Alnylam Pharmaceuticals, Inc. Methods and compositions for delivery of active agents
US20130323269A1 (en) 2010-07-30 2013-12-05 Muthiah Manoharan Methods and compositions for delivery of active agents
CN103370054A (zh) 2010-11-09 2013-10-23 阿尔尼拉姆医药品有限公司 用于抑制Eg5和VEGF基因的表达的脂质配制的组合物和方法
DK3202760T3 (da) 2011-01-11 2019-11-25 Alnylam Pharmaceuticals Inc Pegylerede lipider og deres anvendelse til lægemiddelfremføring
PL2673296T3 (pl) 2011-02-07 2019-03-29 Cerenis Therapeutics Holding Sa Kompleksy lipoproteinowe i ich wytwarzanie oraz ich zastosowania
US9701623B2 (en) 2011-09-27 2017-07-11 Alnylam Pharmaceuticals, Inc. Di-aliphatic substituted pegylated lipids
US9610324B2 (en) * 2012-07-11 2017-04-04 Esperion Therapeutics, Inc. Apolipoprotein mixtures
AU2014259755B2 (en) * 2013-05-01 2018-08-30 Ionis Pharmaceuticals, Inc. Compositions and methods for modulating apolipoprotein (a) expression
EP2853259A1 (en) 2013-09-30 2015-04-01 Université Pierre et Marie Curie (Paris 6) Reconstituted high density lipoproteins composition and uses thereof
SG11201609084QA (en) 2014-05-02 2016-11-29 Cerenis Therapeutics Holding Sa Hdl therapy markers
US11492616B2 (en) * 2016-10-27 2022-11-08 Institute Of Microbiology, Chinese Academy Of Sciences Method for modifying amino acid attenuator and use of same in production
US20190048049A1 (en) 2017-08-10 2019-02-14 Cerenis Therapeutics Holding Sa Cargomers
US20190046608A1 (en) 2017-08-10 2019-02-14 Cerenis Therapeutics Holding Sa Apomers
US11164065B2 (en) 2018-08-24 2021-11-02 Bright Marbles, Inc. Ideation virtual assistant tools
US11461863B2 (en) 2018-08-24 2022-10-04 Bright Marbles, Inc. Idea assessment and landscape mapping
US11189267B2 (en) 2018-08-24 2021-11-30 Bright Marbles, Inc. Intelligence-driven virtual assistant for automated idea documentation
US11081113B2 (en) 2018-08-24 2021-08-03 Bright Marbles, Inc. Idea scoring for creativity tool selection
US20240033322A1 (en) 2020-04-16 2024-02-01 Abionyx Pharma Sa Methods for treating acute conditions using lipid binding protein-based complexes
IL301769A (en) 2020-10-01 2023-05-01 Abionyx Pharma Sa Methods for treating eye diseases by using complexes based on lipid-binding proteins
WO2022219413A1 (en) 2021-04-15 2022-10-20 Abionyx Pharma Sa Use of lipid binding protein-based complexes in organ preservation solutions
WO2023194797A1 (en) 2022-04-06 2023-10-12 Abionyx Pharma Sa Methods for treating eye diseases using lipid binding protein-based complexes
WO2023194798A1 (en) 2022-04-06 2023-10-12 Abionyx Pharma Sa Methods for treating leukocytosis, endothelial dysfunction and carditis using lipid binding protein-based complexes
WO2023237927A2 (en) 2022-06-10 2023-12-14 Abionyx Pharma Sa Methods for treating hyperinflammatory conditions using lipid binding protein -based complexes
WO2023237935A2 (en) 2022-06-10 2023-12-14 Abionyx Pharma Sa Methods for treating acute conditions using lipid binding protein-based complexes

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6198998A (ja) 1984-10-18 1986-05-17 Matsushita Electric Ind Co Ltd 電動送風機
EP0186643A1 (fr) 1984-11-23 1986-07-02 Région Wallonne représentée par l'Exécutif Régional Wallon Procédé de préparation de plasmides vecteurs capables de transformer un hôte bactérien Escherichia coli et d'y promouvoir et contrôler l'expression d'un ADN hétérologue
WO1986004920A1 (en) 1985-02-13 1986-08-28 Biotechnology Research Partners, Limited Human metallothionein-ii promoter in mammalian expression system
WO1987002062A1 (en) 1985-10-04 1987-04-09 Biotechnology Research Partners, Ltd. Recombinant apolipoproteins and methods

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU587989B2 (en) * 1984-10-16 1989-09-07 Mitsubishi Chemical Corporation DMA fragments, expression vectors, proteins, hosts, and process for production of the proteins
GB8507833D0 (en) * 1985-03-26 1985-05-01 Biogen Nv Production of human somatomedin c
GB8625435D0 (en) * 1986-10-23 1986-11-26 Erba Farmitalia Human apolipoprotein ai
EP0269260A3 (en) * 1986-10-29 1988-06-22 Biotechnology Research Partners, Ltd. Apoai-ciii-aiv, apoaii apob, apoci, and ldl receptor polymorphisms for genetic fingerprinting and predictive of atherosclerosis

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6198998A (ja) 1984-10-18 1986-05-17 Matsushita Electric Ind Co Ltd 電動送風機
EP0186643A1 (fr) 1984-11-23 1986-07-02 Région Wallonne représentée par l'Exécutif Régional Wallon Procédé de préparation de plasmides vecteurs capables de transformer un hôte bactérien Escherichia coli et d'y promouvoir et contrôler l'expression d'un ADN hétérologue
WO1986004920A1 (en) 1985-02-13 1986-08-28 Biotechnology Research Partners, Limited Human metallothionein-ii promoter in mammalian expression system
WO1987002062A1 (en) 1985-10-04 1987-04-09 Biotechnology Research Partners, Ltd. Recombinant apolipoproteins and methods

Non-Patent Citations (16)

* Cited by examiner, † Cited by third party
Title
A M MAXAM AND W GILBERT: "A new method for sequencing DNA", PROC NATL ACAD SCI U S A., 1974, pages 560 - 564
BARKER W.C. ET AL.: "Evolution of lipoproteins deduced from protein sequence data", COMP BIOCHEM PHYSIOL, 1977, pages 309 - 315, XP025827046, DOI: doi:10.1016/0305-0491(77)90060-8
BREWER HB JR: "The amino acid sequence of human APOA-I, an apolipoprotein isolated from high density lipoproteins", BIOCHEM BIOPHYS RES COMMUN., 1978, pages 623 - 630, XP024839665, DOI: doi:10.1016/0006-291X(78)91614-5
BROACH JR, STRATHERN JN, HICKS JB.: "Transformation in yeast: development of a hybrid cloning vector and isolation of the CAN1 gene", GENE, pages 121 - 133
BROACH, J. R. ET AL.: "Transformation in yeast: development of a hybrid cloning vector and isolation of the CAN1 gene", GENE, 121-133
GHRAYEB J ET AL.: "Secretion cloning vectors in Escherichia coli", EMBO J., 1984, pages 2437 - 2442
J E MOTT ET AL.: "Maximizing gene expression from plasmid vectors containing the lambda PL promoter: strategies for overproducing transcription termination factor rho", PROC NATL ACAD SCI U S A., 1985, pages 88 - 92, XP001064522, DOI: doi:10.1073/pnas.82.1.88
JEFFREY H. MILLER: "Experiments in Molecular Genetics"
JEFFREY J. SEILHAMER ET AL.: "Isolation and DNA Sequence of Full-Length cDNA and of the Entire Gene for Human Apolipoprotein AIâ€"Discovery of a New Genetic Polymorphism in the apo AI Gene", DNA, 1984, pages 309 - 317
L. VILLA KOMAROFF ET AL.: "A bacterial clone synthesizing proinsulin", PROC. NATI. ACAD. SCI. USA, 1978, pages 3727 - 3731
LORENZETTI R ET AL.: "Expression of the human apolipoprotein AI gene fused to the E. coli gene for beta-galactosidase", FEBS LETT., 1986, pages 343 - 346
MALLORY JB ET AL.: "Expression and characterization of human apolipoprotein A-I in Chinese hamster ovary cells", J. BIOL. CHEM., 1987, pages 4241 - 4247
MANIATIS T. ET AL.: "Molecular cloning"
MATSUURA Y, POSSEE RD, BISHOP DH.: "Expression of the S-coded genes of lymphocytic choriomeningitis arenavirus using a baculovirus vector", J GEN VIROL., 1986, pages 1515 - 1529
P CHEUNG AND L CHAN: "Nucleotide sequence of cloned cDNA of human apolipoprotein A-I.", NUCLEIC ACIDS RES, 1983, pages 3703 - 3715
RÜTHER U, MÜLLER-HILL B.: "Easy identification of cDNA clones", EMBO J., 1983, pages 1791 - 1794

Also Published As

Publication number Publication date
CN88103118A (zh) 1988-12-14
DE3880739T2 (de) 1993-08-19
HU204562B (en) 1992-01-28
LV5288A3 (lv) 1993-10-10
CZ363888A3 (cs) 1998-02-18
NO882341D0 (no) 1988-05-27
EP0293357A1 (fr) 1988-11-30
SK363888A3 (en) 1998-07-08
PL158064B1 (pl) 1992-07-31
SK279166B6 (sk) 1998-07-08
JP2634193B2 (ja) 1997-07-23
CY1809A (en) 1995-10-20
KR880014110A (ko) 1988-12-22
DK289688A (da) 1988-11-29
PT87562B (pt) 1992-09-30
DE3880739D1 (de) 1993-06-09
DK175686B1 (da) 2005-01-17
PL272698A1 (en) 1989-03-06
AU1672388A (en) 1988-12-01
FI882456A (fi) 1988-11-29
CZ283648B6 (cs) 1998-05-13
FI100056B (fi) 1997-09-15
CA1323851C (en) 1993-11-02
DK289688D0 (da) 1988-05-27
GB8712540D0 (en) 1987-07-01
HK137794A (en) 1994-12-16
LTIP828A (en) 1995-02-27
NO882341L (no) 1988-11-29
IL86480A (en) 1992-08-18
CN1031892C (zh) 1996-05-29
EP0293357B1 (fr) 1993-05-05
AU615654B2 (en) 1991-10-10
IL86480A0 (en) 1988-11-15
NO179253B (no) 1996-05-28
NO179253C (no) 1996-09-04
NZ224808A (en) 1990-01-29
ES2054878T3 (es) 1994-08-16
IE62422B1 (en) 1995-02-08
IE881597L (en) 1988-11-28
HUT47153A (en) 1989-01-30
KR970000808B1 (en) 1997-01-20
PT87562A (pt) 1989-05-31
SU1834904A3 (ru) 1993-08-15
JPS6416589A (en) 1989-01-20
US5059528A (en) 1991-10-22
DD291093A5 (de) 1991-06-20
FI882456A0 (fi) 1988-05-25
SG131594G (en) 1995-01-13
ATE89006T1 (de) 1993-05-15
ZA883824B (en) 1989-02-22
UA19765A (uk) 1997-12-25
EG19101A (en) 1994-09-29
RU2009198C1 (ru) 1994-03-15

Similar Documents

Publication Publication Date Title
LT3600B (en) Nucleic acid fragment which codes for human proapolipoprotein a-i
US4743679A (en) Process for producing human epidermal growth factor and analogs thereof
Bürglin et al. The nuclear migration signal of Xenopus laevis nucleoplasmin.
Ullmann One-step purification of hybrid proteins which have β-galactosidase activity
US6331414B1 (en) Preparation of human IGF via recombinant DNA technology
US5100784A (en) Process for the preparation of mature human serum albumin
JPH04503301A (ja) 合成インターロイキン―６
CZ292703B6 (cs) Mutantní proteiny lidského interleukinu-4
US5359033A (en) Cleaved dimers of mullerian inhibiting substance-like polypeptides
US4714674A (en) Chemotactic assay for immunogenicity
PT93956A (pt) Metodo de purificacao de proteinas utilizando fusoes ctap-iii
JP2002538757A (ja) 食欲制御活性を有するポリペプチド
US5656458A (en) Expression and processing of amino terminus acetylated FGF's in yeast
US20030207795A1 (en) Methods for the production of purified recombinant human uteroglobin for the treatment of inflammatory and fibrotic conditions
CA2002210C (en) Expression and processing of authentic fgf's in yeast
JPH0680697A (ja) ヒト好中球エラスターゼ阻害活性を有する天然型ポリペプチドおよびそれを含有する医薬製剤
JPS62158487A (ja) 突然変異体コ−デイング配列
JP2574146B2 (ja) ポリペプチド発現ベクタ−、該ベクタ−で形質転換した宿主及び該宿主によるポリペプチドの製造法
Shibui et al. High-level expression of human proapolipoprotein AI in Escherichia coli using expression plasmids containing tandemly polymerized proapolipoprotein AI structural genes
EP0424512B1 (en) Antimetastatic peptides
EP0676412A1 (en) Purified human chondrocalcin, process for producing the same, and utilization thereof
Calderón-Cacia et al. Incomplete process of recombinant human platelet-derived growth factor produced in yeast and its effect on the biological activity
INUKAI et al. Effects of Inserting Eight Amino Acid Residues into the Major Lipoprotein on Its Assembly in the Outer Membrane of
Stoffel et al. Expression of Human APO AI, AII and CII Genes in Pro-and Eucaryotic Cells
JPS62175181A (ja) ラミニンとその製法

Legal Events

Date Code Title Description
PC9A Transfer of patents

Free format text: 20010321 * MINISTERIE DE LA REGION WALLONNE,BE

MM9A Lapsed patents

Effective date: 20020803